Monday, July 30
4:30 – 6 p.m.
AACC’s Disruptive Technology Award recognizes innovative testing solutions that improve patient care through diagnostic performance or access to high quality testing. The award’s three finalist teams will present data on their technologies during this special session at the 70th AACC Annual Scientific Meeting.
During the session, a panel of expert judges will evaluate and score all presented testing solutions based on feasibility and performance, and the audience will also get a chance to vote for their favorite technology.
The team with the highest score from the judges will win a $5,000 cash prize and the team with the most audience votes will be recognized with an Audience Choice Award plaque. Learn more about the award details.
Congratulations to the three finalists who will present the following technologies:
Ativa has developed a fluid processing engine that allows its MicroLAB to perform the full analytical processes utilized in large core lab blood analyzers entirely on a low-cost disposable card. The significance of this breakthrough is that it enables the major test panels that form the backbone of blood testing to be performed by medical staff at the point of care. Clinics will be able to do real-time testing themselves rather than waiting for a day or more for the traditional blood send-out process. Also, this technology can be integrated with, and significantly expand the reach of, AI-based medicine, telemedicine, and retail clinics.
GNA Biosolutions has created a platform technology, Pulse Controlled Amplification (PCA), that accelerates temperature ramps in nucleic acid amplification by 1,000,000 times. Faster temperature ramps allow for amplification reaction times that are at least 10 times faster than conventional methods. Furthermore, PCA makes it possible to process clinical samples without additional DNA purification and extraction steps. Dangerous pathogens can be detected by PCA in non-traditional testing environments within minutes, with the sensitivity and specificity of laboratory-based molecular diagnostics. GNA Biosolutions is also developing a PCA-powered integrated sample-to-result system for infectious diseases testing at the point of care that is ultrafast, portable, and inexpensive.
Two Pore Guys (2PG) is developing a small (6 in x 6 in) diagnostic device that enables the detection of any molecule of interest, including nucleic acids, proteins, metabolites, drugs, and small molecules. The technology employs solid-state nanopores that enable single molecule counting using purely electrical sensing, obviating the need for optics, chemistries, or electrochemical sensors. 2PG will present data from assays that showcase the strength of the nanopore as a sensor, including single-nucleotide polymorphism quantitation, trait zygosity (plants), circulating tumor DNA detection (i.e. liquid biopsy), and early detection of autoimmune disease (type 1 diabetes) and bacterial infection (Mycobacterium tuberculosis).
A special mention and congratulations to the award semifinalists, who will also be recognized at the Monday, July 30 session. Learn more about the semifinalists’ technologies.
Thank you from AACC to all the applicants who submitted their technology to this competition. We wish you all the best and invite you to apply again in the future.